• Claire, Leurent, Principal, Venture Investments, Johnson & Johnson Innovation
Claire is Principal of Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston MA. Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson.
Prior to joining JJDC, Claire was Investment Director, then Managing Director, at Samsung Ventures with a focus on Life Science, Health Economics and Connected Health sectors. Prior to Samsung Ventures, she spent 14 years in the pharmaceutical industry in R&D. At Pfizer, she led teams in design and implementation of clinical plans from First in Human to Proof of Concept studies with end-to-end accountability for various development programs ranging from small molecules and biologics to digital technologies. Prior to Pfizer, Claire supported large global multicentric phase 3 pre/registration studies and launch activities at Wyeth Pharmaceuticals in Neuroscience and Women Health. Prior to Wyeth, she was Project Manager at Forenap, a neuroscience CRO, where she advanced a portfolio of clinical protocols for diverse global pharma clients. In this position, she acquired first-hand operational experience in clinical trials and oversaw First in Human studies at the Phase 1 center.
Claire earned her PhD in molecular and cellular biology at the Institute of Genetics, Molecular and Cellular Biology (IGBMC) of Strasbourg, France. She also earned a certificate in Pharmacology from La Pitié-Salpêtrière (Paris VI), and the FIEC certificate in Clinical Trial from Louis Pasteur University (ULP, Strasbourg). She earned her MBA at MIT Sloan.”